WATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 7, 2019--
Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company
focused on developing and commercializing novel tetracyclines to treat
serious and life-threatening conditions, today announced that company
management will host a conference call at 4:30 p.m. ET on Thursday,
March 14, 2019 to discuss fourth quarter and full-year 2018 financial
results and provide a general corporate update.
The conference call may be accessed by dialing 844-831-4023 (U.S. and
Canada) or 731-256-5215 (international) and entering conference ID
number 4187876. A live audio webcast of the conference call will be
available online from the “Investors – Events & Presentations” section
of the Tetraphase website at www.tphase.com.
A replay of the conference call will be available from 7:30 p.m. ET on
Thursday, March 14, 2019, through 7:30 p.m. ET on Thursday, March 21,
2019 by dialing 855-859-2056 (U.S. and Canada) and 404-537-3406 for
(international) callers. The conference ID number is 4187876. A replay
of the webcast will be available by visiting Tetraphase’s website.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using
its proprietary chemistry technology to create novel tetracyclines for
serious and life-threatening conditions, including bacterial infections
caused by many of the multidrug-resistant bacteria highlighted as urgent
public health threats by the World Health Organization and the Centers
for Disease Control and Prevention. The Company has created more than
3,000 novel tetracycline compounds using its proprietary technology
platform. Tetraphase's lead product XERAVATM is approved for
the treatment of complicated intra-abdominal infections by the U.S. Food
and Drug Administration and the European Medicines Agency. The Company’s
pipeline also includes TP-271 and TP-6076, which are in Phase 1 clinical
trials and TP-2846 which is in preclinical testing for acute myeloid
leukemia. Please visit www.tphase.com
for more company information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005068/en/
Source: Tetraphase Pharmaceuticals, Inc.